A panel of experts to the Food and Drug Administration has recommended the agency approve a long-acting antibody drug that can protect infants from the seasonal virus, RSV.
Advisers to the US Food and Drug Administration voted Thursday to endorse a monoclonal antibody designed to protect infants and some young toddlers from RSV.
An FDA advisory committee voted in favor of supporting a respiratory syncytial virus therapy designed to protect newborns and infants. The antibody drug developed by partners Sanofi and AstraZeneca is currently under regulatory review.
The U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee voted on Thursday in favor of approving a new respiratory syncytial virus treatment for infants.
AstraZeneca-Sanofi Nirsevimab unanimously recommended by USFDA Advisory Committee for prevention of RSV in infants medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.